Obesity Drugs Show Early Promise Against PMOS
Polyendocrine metabolic ovarian syndrome (PMOS), a hormonal condition formerly known as polycystic ovary syndrome that affects 1 in 8 women worldwide, is showing early response to obesity medications like semaglutide, according to clinical data published in the journal Fertility and Sterility. Researchers led by Dr. Melanie Cree at Children’s Hospital Colorado found that GLP-1 receptor … Read more